Redefining bronchioloalveolar carcinoma

Seminars in Oncology

Volumn 32, Issue 3 SOPEC. ISS, 2005, Pages 329-335

  Laskin, Janessa J ^a,c   Sandler, Alan B ^b   Johnson, David H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG PARENCHYMA; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 20644440179     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.013     Document Type: Article

References (49)

1. N.C. Page, W.L. Read, R.M. Tierney The epidemiology of small cell lung cancer Proc Am Soc Clin Oncol 205a 2002 (abstr 1216)
2. A.A. Liebow Bronchiolo-alveolar carcinoma Adv Intern Med 10 1960 329 358
3. W.D.C. Travis, B. Corrin Bronchioloalveolar carcinoma TV W.D. Travis T.V. Colby WHO International Histological Classification of Tumors (ed 5) 1999 Springer Berlin, Germany 34 38
4. M.I. Ebright, M.F. Zakowski, J. Martin Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma Ann Thorac Surg 74 2002 1640 1646
5. H. Terasaki, T. Niki, Y. Matsuno Lung adenocarcinoma with mixed bronchioloalveolar and invasive components Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization Am J Surg Pathol 27 2003 937 951
6. O. Auerbach, L. Garfinkel The changing pattern of lung carcinoma Cancer 68 1991 1973 1977
7. S.H. Barsky, R. Cameron, K.E. Osann Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features Cancer 73 1994 1163 1170
8. W.D. Travis, J. Lubin, L. Ries United States lung carcinoma incidence trends Declining for most histologic types among males, increasing among females Cancer 77 1996 2464 2470
9. P.A. Wingo, L.A.G. Ries, G.A. Giovino Annual Report to the Nation on the Status of Cancer, 1973-1996, With a Special Section on Lung Cancer and Tobacco Smoking J Natl Cancer Inst 91 1999 675 690
10. W.L. Read, N.C. Page, R.M. Tierney The epidemiology of bronchioloalveolar carcinoma over the past two decades Analysis of the SEER database Lung Cancer 45 2004 137 142
11. J.E. Barkley, M.R. Green Bronchioloalveolar carcinoma J Clin Oncol 14 1996 2377 2386
12. O.S. Breathnach, D.J. Kwiatkowski, D.M. Finkelstein Bronchioloalveolar carcinoma of the lung Recurrences and survival in patients with stage I disease J Thorac Cardiovasc Surg 121 2001 42 47
13. O.S. Breathnach, N. Ishibe, J. Williams Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung Cancer 86 1999 1165 1173
14. A. Morabia, E.L. Wynder Relation of bronchioloalveolar carcinoma to tobacco BMJ 304 1992 541 543
15. R.C. Brownson, T.S. Loy, E. Ingram Lung cancer in nonsmoking women. Histology and survival patterns Cancer 75 1995 29 33
16. M. Palmarini, H. Fan Retrovirus-induced ovine pulmonary adenocarcinoma, an animal model for lung cancer J Natl Cancer Inst 93 2001 1603 1614
17. S.A. Yousem, S.D. Finkelstein, P.A. Swalsky Absence of Jaagsiekte sheep retrovirus DNA and RNA in bronchioloalveolar and conventional human pulmonary adenocarcinoma by PCR and RT-PCR analysis Hum Pathol 32 10 2001 1039 1042
18. Y.W. Cheng, H.L. Chiou, G.T. Sheu The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women Cancer Res 61 2001 2799 2803
19. P. Volpino, N. D'Andrea, R. Cangemi Bronchioloalveolar carcinoma: clinical, radiographic, and pathological findings. Surgical results J Cardiovasc Surg 42 2001 261 267
20. P. Dumont, B. Gasser, C. Rouge Bronchoalveolar carcinoma Histopathologic study of evolution in a series of 105 surgically treated patients Chest 113 1998 391 395
21. Y.Y. Liu, Y.M. Chen, M.H. Huang Prognosis and recurrent patterns in bronchioloalveolar carcinoma Chest 118 2000 940 947
22. J.F. Regnard, N. Santelmo, N. Romdhani Bronchioloalveolar lung carcinoma results of surgical treatment and prognostic factors Chest 114 1998 45 50
23. E.R. Feldman, R.T. Eagan, D.J. Schaid Metastatic bronchioloalveolar carcinoma and metastatic adenocarcinoma of the lung Comparison of clinical manifestations, chemotherapeutic responses, and prognosis Mayo Clin Proc 67 1992 27 32
24. J.B. Sorensen, F.R. Hirsch, J. Olsen The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease Cancer 62 1988 361 367
25. R.B. Vance, J. Crowley, D. Gandara Phase II evaluation of paclitaxel by 96-h infusion in stage IIIb and IV bronchioloalveolar carcinoma 2000 Presented at the World Conference on Lung Cancer, Tokyo, Japan, Sept 11-15
26. K. Kelly, J. Crowley, P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer A Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
27. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
28. G.V. Scagliotti, F. De Marinis, M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Onco 20 2002 4285 4291
29. J.P. Van Meerbeeck, E.F. Smit, P. Lianes An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 308a 2001 (abstr 1228)
30. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
31. C.A. Ritter, C.L. Arteaga The epidermal growth factor receptor-tyrosine kinase A promising therapeutic target in solid tumors Semin Oncol 30 suppl 1 2003 3 11
32. V. Rusch, D. Klimstra, E. Venkatraman Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 1997 515 522
33. G. Fontanini, M. De Laurentiis, S. Vignati Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer Amphiregulin and microvessel count are independent prognostic indicators of survival Clin Cancer Res 4 1998 241 249
34. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
35. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
36. R. Perez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
37. V.A. Miller, M.G. Kris, N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
38. H. West, W.A. Franklin Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer Southwest Oncology Group Study S0126 Proc Am Soc Clin Oncol 618 2004 (abstr 7014)
39. M. Kris, A. Sandler, V. Miller Cigarette smoking history predicts sensitivity to erlotinib Resulsts of a phase II trial in patients with bronchioloalveolar carcinoma Proc Am Soc Clin Ocol 628 2004 (abstr 7062)
40. V.A. Miller, J. Patel, N. Shah The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC) Preliminary results of a phase II trial Proc Am Soc Clin Oncol 619 2003 (abstr 2491)
41. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
42. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
43. R. Perez-Soler The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer Clin Cancer Res 10 suppl 2004 4238s 4240s
44. L.R. Bailey, M. Janas, N. Bindslev Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy Proc Am Soc Clin Oncol 618 2004 (abstr 7013)
45. W.A. Franklin, P.H. Gumerlock, J. Crowley EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC) Analysis of SWOG 9417 and lung SPORE tissue samples Proc Am Soc Clin Oncol 620 2003 (abstr 2493)
46. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr Epidermal growth factor receptor in non-small-cell lung carcinomas Correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807
47. F.R. Hirsch, G.V. Scagliotti, C.J. Langer Epidermal growth factor family of receptors in preneoplasia and lung cancer Perspectives for targeted therapies Lung Cancer 41 suppl 1 2003 S29 S42
48. J.G. Laskin, J. Zubkus Bronchioloalveolar carcinoma Clinical characteristics and tissue microarray patterns, in World Conference on Lung Cancer A Lung Cancer 41 suppl 2003 144
49. F. Cappuzzo, E. Magrini, S. Bartolini Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol 196 2004 (abstr 3004)